CVS Health Corporation $CVS Shares Bought by Calydon Capital

Calydon Capital boosted its holdings in CVS Health Corporation (NYSE:CVS) by 85.9% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 96,416 shares of the pharmacy operator’s stock after purchasing an additional 44,557 shares during the quarter. CVS Health makes up 1.2% of Calydon Capital’s portfolio, making the stock its 23rd biggest holding. Calydon Capital’s holdings in CVS Health were worth $7,269,000 as of its most recent SEC filing.

A number of other hedge funds have also recently added to or reduced their stakes in CVS. Harbor Capital Advisors Inc. lifted its holdings in shares of CVS Health by 72.1% during the 3rd quarter. Harbor Capital Advisors Inc. now owns 339 shares of the pharmacy operator’s stock worth $26,000 after acquiring an additional 142 shares during the period. Corundum Trust Company INC purchased a new stake in CVS Health in the third quarter valued at approximately $29,000. Front Row Advisors LLC increased its position in CVS Health by 436.5% during the second quarter. Front Row Advisors LLC now owns 456 shares of the pharmacy operator’s stock worth $31,000 after purchasing an additional 371 shares during the last quarter. SOA Wealth Advisors LLC. raised its stake in CVS Health by 36.9% during the third quarter. SOA Wealth Advisors LLC. now owns 486 shares of the pharmacy operator’s stock worth $37,000 after purchasing an additional 131 shares during the period. Finally, Twin Peaks Wealth Advisors LLC purchased a new position in CVS Health during the second quarter worth approximately $36,000. 80.66% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

CVS has been the subject of several research reports. Barclays boosted their price objective on shares of CVS Health from $87.00 to $93.00 and gave the company an “overweight” rating in a research note on Wednesday, December 10th. UBS Group reiterated an “outperform” rating on shares of CVS Health in a report on Wednesday, December 10th. JPMorgan Chase & Co. boosted their price target on CVS Health from $93.00 to $101.00 and gave the company an “overweight” rating in a research report on Wednesday, December 17th. Piper Sandler restated an “overweight” rating and issued a $101.00 price objective (up from $99.00) on shares of CVS Health in a report on Wednesday, December 10th. Finally, Argus reduced their price objective on CVS Health from $91.00 to $90.00 and set a “buy” rating on the stock in a research note on Wednesday, January 28th. Twenty equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $95.05.

CVS Health Trading Up 0.1%

NYSE CVS opened at $76.14 on Friday. The stock has a market cap of $96.87 billion, a P/E ratio of 55.17, a PEG ratio of 0.79 and a beta of 0.49. The company’s fifty day simple moving average is $78.17 and its 200-day simple moving average is $77.79. The company has a current ratio of 0.84, a quick ratio of 0.63 and a debt-to-equity ratio of 0.80. CVS Health Corporation has a 52 week low of $58.35 and a 52 week high of $85.15.

CVS Health (NYSE:CVS) last released its quarterly earnings results on Tuesday, February 10th. The pharmacy operator reported $1.09 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.00 by $0.09. CVS Health had a net margin of 0.44% and a return on equity of 11.31%. The firm had revenue of $105.69 billion for the quarter, compared to the consensus estimate of $103.67 billion. During the same quarter in the previous year, the firm posted $1.19 EPS. The firm’s quarterly revenue was up 8.2% on a year-over-year basis. CVS Health has set its FY 2026 guidance at 5.940-6.140 EPS. Equities research analysts predict that CVS Health Corporation will post 5.89 EPS for the current fiscal year.

CVS Health Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Monday, February 2nd. Stockholders of record on Thursday, January 22nd were given a dividend of $0.665 per share. This represents a $2.66 dividend on an annualized basis and a dividend yield of 3.5%. The ex-dividend date of this dividend was Thursday, January 22nd. CVS Health’s payout ratio is presently 192.75%.

CVS Health News Summary

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: Sanford C. Bernstein upgraded CVS to “outperform” with a $94 price target, signaling upward analyst momentum and providing a clear catalyst for investor sentiment. Occidental Petroleum, CVS, Petco: Top Analyst Calls
• Positive Sentiment: CVS announced a new AI-powered health platform, which could boost growth prospects for care management, digital engagement and margin improvement if adoption scales. CVS to launch new AI-powered health platform
• Positive Sentiment: CVS joined an international movement to become menopause accredited, strengthening its clinical services and retail clinic positioning in women’s health — a niche revenue/traffic driver over time. CVS Health joins international movement to become menopause accredited
• Neutral Sentiment: Analysts are revising fair‑value estimates modestly (one update moved fair value ~US$94→US$96), reflecting balanced views: upside from Medicare Advantage exposure but uncertainty on managed‑care earnings and capital allocation. How The CVS Health (CVS) Story Is Shifting With Medicare Advantage And Valuation Debates
• Neutral Sentiment: Competitive dynamics: a North Carolina health plan is triggering a bidding fight for 2028 Aetna/CVS contracts — potential upside if CVS wins, but outcome uncertain. N.C. Health Plan Sparks 2028 Bidding War Over Aetna And CVS Contracts
• Neutral Sentiment: Market reaction since earnings: commentary and data pieces note the stock has moved modestly since last quarter; investors are parsing guidance and EPS trajectory for cues. Why Is CVS Health (CVS) Down 1.7% Since Last Earnings Report?
• Negative Sentiment: Aetna, a CVS subsidiary, agreed to a $117.7M DOJ settlement over alleged inaccurate diagnosis coding in Medicare Advantage — a material legal headline that keeps compliance and MA reimbursement risk on investors’ radar. Aetna’s US$117.7m Settlement Puts CVS Health Compliance In Focus
• Negative Sentiment: Policy risk: CVS warned it may close 100+ Tennessee pharmacies if proposed PBM legislation passes, highlighting state‑level regulatory risk that could reduce retail footprint and revenues in affected markets. CVS threatens to close 100+ Tennessee pharmacies over PBM legislation

CVS Health Company Profile

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.